{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:41:30Z","timestamp":1790642490334,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"am","delay-in-days":223,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDKD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1053\/j.ajkd.2021.06.026","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T07:54:08Z","timestamp":1628754848000},"page":"518-526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study"],"prefix":"10.1053","volume":"79","author":[{"given":"Godela M.","family":"Brosnahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Struemph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel B.","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1053\/j.ajkd.2021.06.026_bib1","first-page":"1356","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2021.06.026_bib2","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2215\/CJN.05900519","article-title":"Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County","volume":"15","author":"Suwabe","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2021.06.026_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1681\/ASN.V8101560","article-title":"Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease","volume":"8","author":"Johnson","year":"1997","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2021.06.026_bib5","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2021.06.026_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"15","key":"10.1053\/j.ajkd.2021.06.026_bib7","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1073\/pnas.86.15.6007","article-title":"Renal epithelial cyst formation and enlargement in\u00a0vitro: dependence on cAMP","volume":"86","author":"Mangoo-Karim","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1053\/j.ajkd.2021.06.026_bib8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V95903","article-title":"Chloride and fluid secretion in polycystic kidney disease","volume":"9","author":"Sullivan","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"14","key":"10.1053\/j.ajkd.2021.06.026_bib10","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad\u00a0Sci USA"},{"issue":"8","key":"10.1053\/j.ajkd.2021.06.026_bib11","first-page":"1591","article-title":"Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin","volume":"466","author":"Mekahli","year":"2014","journal-title":"Pflugers Arch"},{"issue":"25","key":"10.1053\/j.ajkd.2021.06.026_bib12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2021.06.026_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2021.06.026_bib14","doi-asserted-by":"crossref","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell Signal"},{"issue":"4","key":"10.1053\/j.ajkd.2021.06.026_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease. Evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2021.06.026_bib16","doi-asserted-by":"crossref","first-page":"109704","DOI":"10.1016\/j.cellsig.2020.109704","article-title":"Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease","volume":"73","author":"Song","year":"2020","journal-title":"Cell Signal"},{"issue":"12","key":"10.1053\/j.ajkd.2021.06.026_bib17","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI9622","article-title":"Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase","volume":"105","author":"Hallows","year":"2000","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1053\/j.ajkd.2021.06.026_bib18","doi-asserted-by":"crossref","first-page":"F1067","DOI":"10.1152\/ajprenal.00005.2010","article-title":"Role of the energy sensor AMP-activated protein kinase in renal physiology and disease","volume":"298","author":"Hallows","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1053\/j.ajkd.2021.06.026_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.mehy.2009.05.043","article-title":"Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease","volume":"73","author":"McCarty","year":"2009","journal-title":"Med Hypotheses"},{"issue":"6","key":"10.1053\/j.ajkd.2021.06.026_bib20","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib21","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2021.06.026_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct0707092","article-title":"Metformin for the treatment of the polycystic ovary syndrome","volume":"358","author":"Nestler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2021.06.026_bib24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2011-3061","article-title":"Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial","volume":"97","author":"Morin-Papunen","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1053\/j.ajkd.2021.06.026_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2021.06.026_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/pds.3432","article-title":"Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control","volume":"22","author":"Hung","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1053\/j.ajkd.2021.06.026_bib27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/dom.12354","article-title":"Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls","volume":"16","author":"Bannister","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1053\/j.ajkd.2021.06.026_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2021.06.026_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11606-017-4219-3","article-title":"Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease","volume":"33","author":"Marcum","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2021.06.026_bib30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1053\/j.ajkd.2021.06.026_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.13206","article-title":"Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function","volume":"322","author":"Roumie","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.ajkd.2021.06.026_bib32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2337\/dc19-0936","article-title":"The long-term effects of metformin on patients with type 2 diabetic kidney disease","volume":"43","author":"Kwon","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ki.2014.128","article-title":"Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes","volume":"87","author":"Molitch","year":"2015","journal-title":"Kidney Int"},{"issue":"30","key":"10.1053\/j.ajkd.2021.06.026_bib35","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1074\/jbc.M114.567271","article-title":"Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK)","volume":"289","author":"Cao","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?","volume":"19","author":"Pisani","year":"2018","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-018-4509-0","article-title":"Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation","volume":"18","author":"Knight","year":"2018","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1053\/j.ajkd.2021.06.026_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2021.06.026_bib39","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2021.06.026_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.06.026_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"issue":"4","key":"10.1053\/j.ajkd.2021.06.026_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.12854","article-title":"Understanding and overcoming metformin gastrointestinal intolerance","volume":"19","author":"Bonnet","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1053\/j.ajkd.2021.06.026_bib43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1185\/030079904125003278","article-title":"Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study","volume":"20","author":"Blonde","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1053\/j.ajkd.2021.06.026_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.06.026_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000481951","article-title":"Renoprotective effects of metformin","volume":"138","author":"De Broe","year":"2018","journal-title":"Nephron"},{"issue":"6","key":"10.1053\/j.ajkd.2021.06.026_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1389450118666170601130947","article-title":"AMP-activated protein kinase as a drug target in chronic kidney disease","volume":"19","author":"Allouch","year":"2018","journal-title":"Curr Drug Targets"},{"issue":"9","key":"10.1053\/j.ajkd.2021.06.026_bib47","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1681\/ASN.2018010050","article-title":"Phosphorylation of acetyl-CoA carboxylase by AMPK reduces renal fibrosis and is essential for the anti-fibrotic effect of metformin","volume":"29","author":"Lee","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2021.06.026_bib48","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1161\/CIRCULATIONAHA.118.035525","article-title":"Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus","volume":"138","author":"Bjornstad","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2021.06.026_bib49","first-page":"833A","article-title":"Effect of metformin on the progression of autosomal dominant polycystic kidney disease (ADPKD) [ASN abstract 1774]","volume":"26","author":"Brosnahan","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2021.06.026_bib50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.34067\/KID.0004002020","article-title":"Baseline characteristics and patient-reported outcomes of ADPKD patients in the multicenter TAME-PKD clinical trial","volume":"1","author":"Seliger","year":"2020","journal-title":"Kidney360"},{"issue":"3","key":"10.1053\/j.ajkd.2021.06.026_bib51","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621007903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621007903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:25:51Z","timestamp":1721024751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621007903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0272638621007903"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.026","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}